Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)

NCT01621490 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT01621490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01621490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2012
Completion date
October 25, 2018
Enrollment
170 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, metastatic melanoma